[go: up one dir, main page]

EP1673080A2 - Preparation pharmaceutique combinee contenant de l'acide glycyrrhizique, du zinc et un compose renfermant un groupe thiol ou un groupe pouvant etre metabolise en groupe thiol - Google Patents

Preparation pharmaceutique combinee contenant de l'acide glycyrrhizique, du zinc et un compose renfermant un groupe thiol ou un groupe pouvant etre metabolise en groupe thiol

Info

Publication number
EP1673080A2
EP1673080A2 EP04764772A EP04764772A EP1673080A2 EP 1673080 A2 EP1673080 A2 EP 1673080A2 EP 04764772 A EP04764772 A EP 04764772A EP 04764772 A EP04764772 A EP 04764772A EP 1673080 A2 EP1673080 A2 EP 1673080A2
Authority
EP
European Patent Office
Prior art keywords
combination preparation
thiol group
group
zinc
free thiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04764772A
Other languages
German (de)
English (en)
Inventor
Dana Flavin-Koenig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1673080A2 publication Critical patent/EP1673080A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to a pharmaceutical or nutritional supplement combination which contains glycyrrhizic acid, zinc and a compound acceptable for oral administration with at least one free thiol group or a group which is metabolized in the body of a mammal to a free thiol group.
  • the invention further relates to the use of such a preparation in combating viral diseases, in particular flu-like viral diseases.
  • Glycyrrhizic acid (or Glycyrrhizin) is an essential part of the root of Glycyrrhizia glabra LINNE (in colloquial language: licorice herb) with the following structural formula:
  • the unpeeled, dried roots of Glycyrrhizia glabra are called liquorice roots and used as a drug in natural medicine.
  • Liquid and solid forms for oral use are called Succus Liquiritiae.
  • Licorice is made from this Succus Liquiritiae with concentrations of glycirrhizic acid of up to more than 1%.
  • Oxopathic areas of application of licorice root are catarrhs of the upper airways and ulcers of the stomach and duodenum. In catarrhs, the secretolytic, expectorant and anti-inflammatory effects of the drug are in the foreground.
  • Glycyrrhizic acid itself has shown an interferon-inducing effect in animal experiments, which is associated with an antiviral effect. It is also said to have direct antiviral activity.
  • Zinc is known to be a trace element that is essential for the immune system. If zinc is taken in the event of a virus infection, the interferon activity can be increased many times over. In addition, zinc has direct antiviral activity at the replication level of viruses.
  • Thiol-containing compounds have a number of therapeutic effects.
  • it is particularly important that thiol groups reduce the number of functional antiviral lymphocytes, e.g. of Th-1 lymphocytes and natural killer cells, and thus also increase the source of interferons, in particular interferon ⁇ and interferon y.
  • the increase in the number of functional immune cells is the result of the binding of nitrogen oxide (NO) by the thiol group.
  • NO nitrogen oxide
  • the concentration of NO is increased in viral infections and is responsible for immobilization of antiviral lymphocytes, which weakens the natural endogenous defense against viral infections.
  • a combination of glycyrrhizic acid, glycine and cysteine is on the market in Japan and is used to treat chronic viral hepatitis and posthepatic cirrhosis.
  • the object of the invention is to provide an antiviral agent create that contains a synergistic combination of individual substances, which exceeds the antiviral effect of the individually administered individual substances.
  • the applicant has surprisingly discovered that the combination of the active ingredients glycyrrhizic acid, zinc and a compound which contains a thiol group or a group which can be metabolized to a thiol group has a very excellent antiviral activity.
  • the combination of the active substances can, according to the invention, be in the form of 3 separate preparations of the active substances, which are present in a single packaging unit.
  • any 2 of the active ingredients can also be combined in one composition.
  • all 3 active ingredients can be combined in a single composition.
  • glycyrrhizic acid is preferably used in the form of Succus Liquiritiae.
  • Succus Liquiritiae is available as a juice and as a dried powder, which, as mentioned above, is obtained from the licorice root.
  • a preferred Succus Liquiritiae juice contains 5% glycyrrhizic acid (50 mg / ml).
  • the oral dosage of glycyrrhizic acid for adults is preferably 1500 mg to 2000 mg per day. This dose is preferably administered in two or more doses per day, particularly preferably in three doses.
  • Zinc can be present in the usual combination pharmaceutically acceptable forms, such as zinc orotate, zinc aspartate, zinc histidinate, zinc gluconate and zinc sulfate, in the combination preparation according to the invention.
  • the preferred oral dosage for adults is 75 mg to 150 mg per day (based on the element zinc). Even the daily dose of zinc is preferably divided into several administrations, for example three times a day.
  • Thiol group is metabolized, is preferably selected from N-acetylcysteine, methionine, cysteine, allylcysteine, alpha-lipoic acid and sulfur.
  • N-Acetylcysteine is very particularly preferred since it also has a secretolytic effect. All preparations available on the market, for example ACC ® from Hexal, Fluimucil ® from Zambon etc. are suitable.
  • These compounds are preferably administered in adults at an oral daily dose of 1200 mg to 2400 mg, which is preferably for several administrations per day, e.g. three, is distributed.
  • the daily doses of the listed individual substances for children are preferably half of the adult dose.
  • the combination preparation according to the invention can optionally contain further pharmaceutical active ingredients, e.g. Paracetamol or acetylsalicylic acid.
  • further pharmaceutical active ingredients e.g. Paracetamol or acetylsalicylic acid.
  • the active substances of the combination preparation according to the invention are preferably in a form suitable for oral administration, although a parenteral, topical, intranasal, intravaginal and rectal form of administration are not excluded.
  • Oral forms of administration include tablets, capsules, pills, buccal tablets, elixirs, suspensions, syrups and the like.
  • These forms of administration can include suitable carriers, for example dicalcium phosphate, binders such as gum tragacanth, gum arabic, corn starch or gelatin, disintegrants such as corn starch, potato starch and alginic acid, lubricants such as magnesium stearate, sweetener. ßstoff, flavoring and all other excipients customary in pharmacy include.
  • the combination preparation according to the invention is used to combat acute and chronic, preferably acute, viral diseases which, for example, but not limited to, coroan viruses, rhinoviruses, coxsackieviruses, influenza A and B viruses, herpes viruses, cytomegaloviruses, hepatitis A -, B and C viruses, Epstein-Barr viruses and other colds and flu viruses are caused.
  • acute and chronic, preferably acute, viral diseases which, for example, but not limited to, coroan viruses, rhinoviruses, coxsackieviruses, influenza A and B viruses, herpes viruses, cytomegaloviruses, hepatitis A -, B and C viruses, Epstein-Barr viruses and other colds and flu viruses are caused.
  • viral diseases which, for example, but not limited to, coroan viruses, rhinoviruses, coxsackieviruses, influenza A and B viruses, herpes viruses, cytomegaloviruses, hepatitis A -, B
  • Zinc as a single treatment 125 mg per day, divided into three doses; slight reduction in the duration of the illness to an average of 5 days. On a scale of 1 to 10 (1 least effective, 10 maximum effective): 2
  • N-acetylcysteine 2400 mg divided into three doses; moderate reduction in the duration of the illness to an average of 4 days.
  • the average duration of illness when treated with the combination according to the invention of all three active substances a), b) and c) mentioned above was reduced to about 24 hours or less in the majority of all cases. More specifically, 30 adults (men and women) showed symptom improvement (alleviation of tiredness and weakness) as early as 30 to 60 minutes after taking the first dose of the combination of a), b) and c). 24 hours later, 85% of the patients were able to return to work after the symptoms were completely eliminated. In a few cases, the maximum required duration of treatment was 5 days.
  • the preparation of the invention is of great economic importance apart from its high benefit for the sick person, since the symptoms of the most common diseases leading to incapacity to work (colds, flu infections) can be eliminated in a very short time. No side effects were observed during the administration period.
  • the combined single dose administered was about 500 mg glycyrrhizic acid (or about 10 ml (a small tablespoon) Succus Liquiritiae depuratus solutus 1 + 1 from Chemische Fabrik Dr. Hetterich GmbH & Co. KG, Fuerth, Bavaria), 50 mg zinc (calculated as an element; in the form of zinc orotate) and 800 mg N-acetylcysteine.
  • a 12 year old girl showed symptoms of mild fever, lethargy, fatigue, myalgia, sore throat and general malaise due to a viral infection (Streptococcus negative). It was treated with half of the combined single dose given above and felt better within an hour. Treatment was repeated every 6 hours (except at night). get. After 24 hours it showed a general improvement and no symptoms of a virus infection and could go back to school.
  • a 58-year-old man showed flu-like symptoms, including mild fever, malaise, fatigue, myalgia, headache, and sore throat.
  • the combined single dose given above was given three times throughout the day. After the first morning treatment, the symptoms of fatigue and discomfort improved within 30 minutes, but he was still weak and rested all day. The next day he felt 80% better, but stayed home in the morning and then went to work in the afternoon.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Préparation combinée pharmaceutique ou sous forme de complément alimentaire qui contient de l'acide glycyrrhizique, du zinc et un composé acceptable pour l'administration orale renfermant au moins un groupe thiol libre ou un groupe métabolisé en un groupe thiol libre dans le corps d'un mammifère. Ladite préparation est utile pour lutter contre des maladies virales, en particulier de type grippal.
EP04764772A 2003-09-04 2004-09-03 Preparation pharmaceutique combinee contenant de l'acide glycyrrhizique, du zinc et un compose renfermant un groupe thiol ou un groupe pouvant etre metabolise en groupe thiol Withdrawn EP1673080A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10340845A DE10340845A1 (de) 2003-09-04 2003-09-04 Pharmazeutisches Kombinationspräparat, enthaltend Glycyrrhizinsäure, Zink und eine Verbindung, die eine Thiolgruppe oder eine zu dieser metabolisierbare Gruppe enthält
PCT/EP2004/009814 WO2005023240A2 (fr) 2003-09-04 2004-09-03 Preparation pharmaceutique combinee contenant de l'acide glycyrrhizique, du zinc et un compose renfermant un groupe thiol ou un groupe pouvant etre metabolise en groupe thiol

Publications (1)

Publication Number Publication Date
EP1673080A2 true EP1673080A2 (fr) 2006-06-28

Family

ID=34223349

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04764772A Withdrawn EP1673080A2 (fr) 2003-09-04 2004-09-03 Preparation pharmaceutique combinee contenant de l'acide glycyrrhizique, du zinc et un compose renfermant un groupe thiol ou un groupe pouvant etre metabolise en groupe thiol

Country Status (4)

Country Link
US (1) US8268363B2 (fr)
EP (1) EP1673080A2 (fr)
DE (1) DE10340845A1 (fr)
WO (1) WO2005023240A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592479B2 (en) * 2000-10-31 2013-11-26 Hill's Pet Nutrition, Inc. Antioxidant-containing food composition for use in enhancing antiviral immunity in companion animals
BE1016468A5 (nl) * 2005-02-25 2006-11-07 Raf Gijsemans Samenstelling voor de behandeling en de voorkoming van virale infecties.
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
WO2014197485A1 (fr) * 2013-06-03 2014-12-11 Ansun Biopharma, Inc. Produit thérapeutique antiviral pour infection de l'œil
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
US11253534B2 (en) * 2020-03-23 2022-02-22 Sabine Hazan Method of preventing COVID-19 infection
US11278520B2 (en) 2020-03-31 2022-03-22 Sabine Hazan Method of preventing COVID-19 infection
DE102023001399B4 (de) 2023-04-08 2024-12-24 Peter Meyer Aminosäurenkombination mit Vitaminen, Mineralien und Spurenelementen zur kurativen und rehabilitativen Behandlung von Post-COVID-Syndrom, Post-COVID-19-Syndrom undPost-Vaccine-Syndrom.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB841058A (en) * 1955-10-26 1960-07-13 Percy George Weston Improved mineral food supplements for sheep and cattle and licks incorporating such supplements
CN1080174A (zh) * 1992-06-16 1994-01-05 陈理森 治愈寻常型银屑病外用膏的配制方法
US5770217A (en) * 1997-07-02 1998-06-23 Atlatl, Inc. Dietary supplement for hematological, immune and appetite enhancement
EP0891719A1 (fr) * 1997-07-14 1999-01-20 N.V. Nutricia Composition dietique contenant de la methionine
US20020136782A1 (en) * 2001-01-18 2002-09-26 Fleischner Albert M. Composition patent for solid-dosage form of weight loss product
KR100474945B1 (ko) 2002-01-10 2005-03-10 알앤엘생명과학주식회사 젖소의 원유 중 체세포 감소용 및 유방염의 예방 또는치료용 조성물

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Bharata Bhaisajya Ratnakara", vol. 2ND, August 1999, pages: 261
"Rasatantrasarah Evam Siddhaprayogasamgrahah", vol. II, 1990, pages: 223
ABU IBN-E-SINA: "Al-Qaanoon-fil-Tibb", vol. V, 1996, pages: 127 - 128
ABU SINA: "Al-Qaanoon-fil-Tibb", vol. V, 1996, pages: 127
DATABASE TKDL [online] "Agraas-e-Ambaraarees Digar", XP003027434, Database accession no. AH2/278
DATABASE TKDL [online] "Agraas-e-Ambarbaares", XP003027433, Database accession no. AH2/277
DATABASE TKDL [online] "Kaphanasaka Kvatha", XP003027436, Database accession no. RS21/233
DATABASE TKDL [online] "Patoladikvathah", XP003027437, Database accession no. RG/908
DATABASE TKDL [online] "Safoof Mudir", XP003027435, Database accession no. MH5/1993
MOHAMMAD AKBAR ARZAM: "Qaraabaadeen Qaadri", 1968, pages: 281
Retrieved from the Internet <URL:http://www.healthline.com/health/acute-upper-respiratory-infection#RiskFactors4> *

Also Published As

Publication number Publication date
WO2005023240A2 (fr) 2005-03-17
DE10340845A1 (de) 2005-03-31
US20070031510A1 (en) 2007-02-08
US8268363B2 (en) 2012-09-18
WO2005023240A3 (fr) 2005-10-06

Similar Documents

Publication Publication Date Title
DE60119534T2 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
DE3705151A1 (de) Warzenmittel
EP0989856A1 (fr) Procede et substances pour liberer un facteur de croissance issu des cellules endotheliales, facteur de croissance libere selon ce procede, et son utilisation
EP1673080A2 (fr) Preparation pharmaceutique combinee contenant de l&#39;acide glycyrrhizique, du zinc et un compose renfermant un groupe thiol ou un groupe pouvant etre metabolise en groupe thiol
DE69730214T2 (de) Zusammensetzung und verfahren zur behandlung von herpes simplex
RU2385733C1 (ru) Лечебно-профилактическое средство для молодняка сельскохозяйственных животных и способ профилактики респираторных болезней телят с его применением
US7205009B2 (en) Composition for treating hair and scalp and method for preparing same
DE69902879T2 (de) Pflanzliches antivirales mittel
DE69328102T2 (de) Verwendung von gift aus hautflüglern (hymenopteren) zur herstellung eines medikamentes zur behandlung von infektionen durch dna-viren
Tierra Echinacea: an effective alternative to antibiotics
Khan et al. Rationalistic approach in COVID-19 prevention through intervention of Unani medicine prevalent in epidemic–a review
EP1295601A1 (fr) Composition pharmaceutique a base d&#39;un compose anti-inflammatoire non steroide
EP2900209B1 (fr) Composition à teneur en lysine en tant que complément alimentaire ou pour le traitement de l&#39;herpès
CN1247222C (zh) 治疗艾滋病的药物组合物
DE69223152T2 (de) Buchsbaum zubereitung für die behandlung von hiv infektion
EP2548564B1 (fr) Produit pharmaceutique, alimentation d&#39;un patient et procédé de réduction du poids
CN100443093C (zh) 治疗艾滋病的药物
US20110229584A1 (en) Compound for the control of herpes simplex virus using glycyrrhizic acid, lipoic acid, allantoin, and slippery elm
DE4329857A1 (de) Verbindung zur Stärkung des Immunsystems und von Immunrekationen
EP2796143B1 (fr) Médicament homéopathique pharmaceutique pour la réduction du poids
RU2371192C1 (ru) Лекарственное средство, стимулирующее защитные силы организма, и способ коррекции вторичных иммунодефицитов с его применением
AT500435B1 (de) Aphrodisiakum
CN121102331A (zh) 治疗或预防皮肤瘙痒的药物组合物及其制备方法和应用
CN1177592C (zh) 红芪提取物总皂甙在制备治疗心肌炎药物中的应用
CN1112199C (zh) 一种治疗皮肤病的外用药

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060330

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20091116

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180404